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Liver transplantation services have continued to ex-
pand during the past year as indications for liver re-
placement have broadened, contraindications have 
diminished, and referrals to transplant centers have in-
creased. The UNOS Liver Transplant Registry began 
collecting data officially on October 1, 1987 and by Sep-
tember 30, 1988 had received registration forms for 
1,090 new patients from 42 centers in 23 states (Fig. 1). 
At this rate we estimate that approximately 1 ,400 liver 
transplantations will have been performed in 1988 in the 
United States. 
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Fig ,_ First year new patient registrations 
In the UNOS LIver Transplant Registry. 
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Liver transplantation activity has also increased in 
Europe. The results for 1,238 patients receiving liver 
transplants at 32 European centers (Fig. 2) were 
described in the first report of the European Liver 
Transplant Registry in 1987 (1). In an update presented 
at the Congress of the Transplantation SOciety in 
Australia in 1988, Bismuth reported that the registry had 
grown to 2414 transplantations performed by 49 centers 
as of April, 1988 (2). 
Fig 2. Liver Transplant Centers reporting 
In the European Liver Transplant Registry. 
From Sismuth H, et al .1 
Clinical Transplants 1988, P. Terasaki, Ed. UCLA Tissue Typing Laboratory, Los Angeles, California. 
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~ismuth H. elll. Lance12:674-6. 1987. 
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Expected one year patient survival after liver 
transplantation in reported series ranges from 44 to 
85% as shown by the examples in Table 1. Com-
parison of series is difficult because of substantial dif-
ferences in case mix, time period, and methods of im-
munosuppression. The lower survival rates in some 
reports usually reflect start up experience or include 
cases from prior to 1984 when cyclosporine was not yet 
generally available in the United States and the risk fac-
tors associated with liver transplantation were not as 
clearly delineated. One year survival for cases after 
1984 in the European registry is over 60% compared to 
the overall 1 year patient survival of only 44% (Fig. 3). 
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Fig 3. Patient survival before and 
after 1984 In the European liver reg-
Istry. From Bismuth H, et al.1 
UCLAc Europaa' BCl" Pittsburgh 
(Boston) 
83 1218 41 1258 
100 1315 47 1619 
88% 
73% 44% 54% 73 Ok 
In the Cambridge-Kings College Hospital experience, 
the reported one year survival for patients receiving 
transplants in 1986-87 is 69% (3). 
Case mix is probably the most important factor deter-
mining center specific results and is difficult to analyze. 
However, as larger series are reported such as those 
from Pittsburgh, Cambridge, and Hannover, certain 
trends are becoming clear. 
Survival is significantly affected by the indication for 
transplantation. Among adult patients transplanted in 
Pittsburgh since 1981, four groups of patients can be 
identified (Fig. 4): 1) cancer patients. 2) hepatitis B-virus 
(HBV) surface antigen positive (HBsAg+) patients, 3) 
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Fig 4. Adult patient survival In the Pitts-
burgh series for malignant tumors, chronic 
hepatitis B (HBV), acute liver failure, end 
, . 
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Table 2. Comparison of patient survival rates for benign and malignant diseases of the liver in 
the Pittsburah and CambridaelKino's Col/eae series. 
. 30 dav survival One year survtval I; •• ••· .••••••••• : ••••••••••.••••••••••.•••••.••••••••••...... ...•. Malianant Benian Malianant Benian 
Pittsburgh 92% 88% 
Cambridge/ 
Kina's CoIleoea 
80% 70% 
-.=riend PJ, at aI. Transplant Proc, In press. 
acute hepatic failure patients, and 4) those receiving 
transplants for other chronic liver diseases (primary 
biliary cirrhosis, sclerosing cholangitis, metabolic errors, 
alcoholic and other non-HBV causes of cirrhosis, etc.). 
There is already an extensive literature on transplanta-
tion concerning the fourth group of patients but a brief 
commentary on liver transplantation in the management 
of variceal hemorrhage and for alcoholic cirrhosis is 
warranted. 
LIVER TRANSPLANTATION IN 
ADULTS 
Transplantation for Cancer 
Thirty day survival after liver transplantation for 
malignant liver tumors has been very high but long term 
survival has been disappointing because of the high in-
cidence of tumor recurrence, usually within 18 to 36 
months in most reported series, and because of a ten-
dency of the cancers to recur in the transplanted liver 
(4-8). Thirty-day and one year patient survivals after 
transplantation for malignant and benign disease for the 
Pittsburgh and Cambridge/Kings Hospital series are 
shown in Table 2. 
Factors influencing survival include histologic cell 
type, concurrent cirrhosis, and involvement of regional 
lymph nodes. Pichlmayr has recently reported some 
success with liver transplantation for cancer (9). In a 
series of 95 patients receiving transplants for malignan-
cy, 22 survived more than one year and 10 more than 2 
years, 5 more than 3 years, and 4 more than 5 years. 
Of particular note, he reported 54% one year survival in 
patients with carcinomas of the central bile duct and im-
59% 72% 
30% 50% 
proved one year survival to 91% in patients with cancer 
free regional lymph nodes. Best results for hepatocel-
lular cancer were obtained in patients without concur-
rent cirrhosis. 
We still have much to learn about the behavior of 
cancer in patients receiving transplants and im-
munosuppressive drugs. It has generally been as-
sumed that the immunosuppressive drugs required after 
liver transplantation would promote tumor growth by fur-
ther weakening of immunological defense mechanisms. 
If this were the case, one might expect that the more ef-
ficacious immunosuppression afforded by cyclosporine 
would have a further adverse effect on both tumor free 
interval and patient survival after liver transplantation. 
However, the Cambridge/King's Hospital group recently 
compared patients getting liver transplants for 
hepatocellular carcinoma under azathioprine-pred-
nisone with those getting cyclosporine-Iow dose pred-
nisone (10). The proportion of patients with cirrhosis 
and with fibrolamellar hepatoma and the median tumor 
sizes were similar in both groups. The mean oncologic 
free interval and the length of asymptomatic recurrence 
were significantly longer in the cyclosporine treated 
patients. It was therefore suggested that tumor growth 
rates are lower under cyclosporine-prednisone therapy 
than under azathioprine-steroid therapy. 
The frequency of microscopic regional lymph node 
involvement which cannot be detected preoperatively 
suggests that an extended surgical approach might be 
of benefit in the treatment of patients with hepatic 
tumors unsuitable for subtotal hepatic resection. En-
couraged by recent experience with multiple abdominal 
visceral transplantation in small children with short gut 
syndrome (11,12), Starzl has performed a series of 
cluster organ grafts in a series of 11 patients with sar· 
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Fig 5. LIver-pancreas "cluster" organ 
fran lant. 
comas or carcinoid tumors of the pancreas or 
duodenum and liver metastasis. bile duct carcinomas 
with liver metastasis, or hepatocellular carcinomas with 
invasion of duodenum and colon (13). The native liver. 
pancreas, duodenum, spleen, stomach, proximal 
jejunum and ascending and transverse colon were 
resected en bloc and replaced by a composite cluster 
consisting of liver, pancreas, and duodenum removed 
en bloc from the donor (Fig. 5). Nine of the 11 patients 
have survived and are tumor free one to six months 
after surgery. Thus, the technical feasibility of the 
cluster graft has been established. The impact on 
tumor free interval and long term survival remains to be 
seen. 
Transplantation for Chronic B-virus Hepatitis 
(CAH-HBV) 
About 10% of patients infected with HBV develop a 
chronic carrier state and approximately half of these go 
on to chronic active hepatitis and cirrhosis. Integration 
of the viral genome may be causally related to the later 
development of hepatocellular carcinoma. Even HBV 
carriers who do not develop cirrhosis are at increased 
risk of hepatocellular cancer (14). 
HBV is a double stranded DNA virus. The hepatitis 
delta virus (HOV) is an incomplete RNA virus which can 
only enter mammalian cells in the presence of HBsAg 
and cannot cause infection without prior or concurrent 
infection by HBV. The cellular injury produced by HBV 
is believed to be immunologically mediated by T-cells 
which produce immune lysis of hepatocytes displaying 
viral antigens on the cell surface in association with 
HLA antigens. HOV, however, is a virulent infection with 
direct cytopathic effects and can produce cell injury in-
dependent of immunological mechanisms (14). 
After liver transplantation, most patients with CAH-
HBV retain the carrier state and there is a high in-
cidence of reinfection (5,6,15-19). Thus. recurrent 
hepatitis is a common cause of graft loss more than six 
months after transplantation. Nevertheless. a sig-
nificant number of patients may persist with a low grade 
hepatitis for years after transplantation but with an ex-
cellent quality of life. 
A variety of approaches have been tried to prevent 
or modify HBV reinfection after liver transplantation, in-
cluding hyperimmune globulin (HBIG) or interferon 
therapy. The Milan group has reported its experience 
with 14 HBsAg positive patients treated with both pas-
sive and active immunization beginning during the an-
hepatic phase of surgery and found clearing of HBsAg 
in some patients (17). Five patients cleared HBsAg 
from their sera with three patients survivng out to 9, 19, 
and 20 months followup. One patient died of tumor 
recurrence and another of septic complications. Three 
of the long term survivors have surface antibody 
(HBsAb). 
Rizzetto et al have reported a series of 7 patients 
positive for HOV-RNA prior to transplantation (18). Two 
patients have survived for more than a year without 
detectable HDV or HBV. Three of the five patients with 
reinfection developed clinical hepatitis. 
The Hannover group has also treated 14 patients 
with combined passive and active immunization (19). In 
13 of the patients. a transient decrease in the titer of 
HBsAg was observed and 10 had detectable hepatitis B 
surface antibodies (HBsAb). Six patients survived more 
than 3 months and all had detectable HBsAg within 6 to 
9 weeks after transplantation. Three long term sur-
vivors are rehabilitated despite a chronic carrier state 
and mild hepatitis related enzyme abnormalities. 
The Hannover results are similar to our own ex-
perience in the Pittsburgh series where the chronic car-
rier state continues in nearly all patients after transplan-
tation and an unpredictable but significant percentage 
of patients are able to persist indefinitely despite rein-
fection of the graft. Given the variability of outcome, it 
seems imprudent to deny liver transplantation to HBsAg 
positive patients with end stage cirrhosis, since no other 
therapy is available that offers them a better chance of 
survival. 
It is important to study liver tissue carefully in all 
patients transplanted for HBV. Although it is unusual for 
patients who develop HBsAb to have detectable viral 
antigen, patients with HIV infection have been reported 
to revert from an immune state to an active carrier state. 
Immunosuppression could produce the same result with 
HBV. Secondly, viral antigen may be discovered in liver 
tissue even though absent from serum. Finally, in two 
patients in the Milan series, HDV was subsequently 
found in the allograft despite absence of detectable 
HBV in plasma or the liver. This unusual finding might 
be unique to the transplant situation or might represent 
suppression of HBV by virulent HDV infection. 
A probable flaw in the use of commercial HBIG 
preparations has been that the dose required to neutral-
ize virus may be so large as to be impractical to ad-
minister. A human monoclonal anti-HBsAg antibody 
has been developed by the Sandoz Corporation that 
has 50,000 times the potency of commercial HBIG (20). 
The agent has been used in two patients by Starzl. 
One cleared HBsAg but died of recurrent hepatoma 
after relatively short followup. Another patient cleared 
antigen for 5 months before it was again detected in low 
titer and HBcAg was found on liver biopsy. It is not yet 
known what effects treatment with this agent will have 
on the clinical course of reinfection by HBV after 
transplantation. Clinical trials will continue in 1989. 
Transplantation for Fulminant Hepatic Failure 
Acute fulminant hepatic failure is defined as severe 
liver dysfunction progressing to advanced hepatic en-
cephalopathy within 8 weeks of onset of symptoms in 
the absence of previous liver disease. Subacute ful-
minant hepatic failure is defined as irreversible liver 
failure within 8 to 28 weeks from onset of symptoms. 
Liver transplantation for cancer and for HBV related cir-
rhosis are both characterized by a high late mortality 
from recurrent disease. In contrast. transplantation for 
acute or subacute fulminant hepatic failure is as-
sociated with high early mortality related to the difficult 
circumstances of urgent surgery in high risk. acutely ill 
patients. but excellent long term survival (Fig. 4). The 
difficulty in regard to patients with acute hepatic failure 
concerns how to determine who will recover without 
transplantation and who will not. 
The more common causes of acute fulminant 
hepatic failure include viral infection (A, B or nonA, 
nonB types), drug overdosage or hypersensitivity or ex-
posure to other chemical toxins, and metabolic disor-
ders, especially acute Wilson's disease. liver function 
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Fig 6. Survival for acute fulminant liver 
failure for transplanted versus not trans-
planted patients (pittsburgh serles). From 
Peleman RR, et a/. 21 
9 
studies including asparate aminotransferase (AST), 
alanine aminotransferase (ALT) and prothrombin time 
are quite variable in acute hepatic failure and are often 
not a reliable quide to prognosis. It is common with 
acetaminophen and mushroom poisoning to find ex-
tremely high enzyme levels or prolongation of prothrom-
bin time but recovery without transplantation often oc-
curs. 
Of 29 patients admitted to the heptatology service at 
Presbyterian-University Hospital between February, 
1981 and July. 1985 for fulminant hepatiC failure. only 3 
recovered without transplantation (one patient with 
acute Wilson's disease - the only such recovery yet 
reported. one with halothane hepatitis. and one with 
acetaminophen toxicity) (21). In contrast. 13 patients 
died awaiting transplantation. Patients getting a 
transplant spent less time in the intensive care unit, less 
time on ventilatory support. and fewer days in coma 
despite a longer hospital course than those not getting a 
transplant. Survival for the patients getting a transplant 
was 54% compared to 19% for those who did not (Fig. 
6). Similar survival rates of 55 to 70% have been 
reported in other series (22-24). Withholding of 
transplantation in circumstances of uncertainty is 
probably more dangerous than aggressive efforts to 
perform transplantation in most patients with fulminant 
liver failure. 
GORDON AND STARZL 
Some guides to choice of therapy do exist. Although 
recent study of charcoal hemoperfusion in acute 
'patic failure failed to demonstrate a significant benefit 
this method, the study revealed important prognostic 
')rmation (25). Included were 85 cases of acute 
etaminophen toxicity, 6 cases of acute hepatitis A 
AV), 18 cases of acute HSV (one with HDV also), 20 
ses of non-A, non-S hepatitis (NANB), and 8 cases of 
lothane or other drug toxicity. 
Recovery with medical therapy was highest for 
tients with acute hepatitis A (66.7%) and 
etaminophen overdose (52.9%), intermediate for 
'patitis B (38.9%), and poorest for acute non-A, non-S 
:patilis (20.0%) and other drug or chemical toxins 
2.5%) (Fig. 7). Cerebral edema, renal failure and me-
bolic acidosis provided useful guides to prognosis. 
~covery in patients with acetaminophen toxicity with 
'rebral edema but without renal failure or metabolic 
idosis was 71.4% but fell to 52.5% in patients with 
nal failure and 6.7% in patients with metabolic 
~idosisK Patients with acute hepatitis A or B with 
~rebral edema and renal failure had only a 30% rate of 
covery (Fig. 8). 
In general, most patients with acute acetaminophen 
xicity or acute hepatitis A will recover. Patients with 
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Fig 7. Serial survival rates for the major 
etiologies of fulminant hepatic failure. From 
O'Grady JG, et al.25 
acute non-A, non-S related fulminant hepatic failure 
have a poor prognosis without transplantation. 
Hepatitis B induced fulminant liver failure can be difficult 
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Fig 8. Correlation between survival and complications present in the main etiologic subgroups 
of fulminant hepatic failure. Form O'Grady JG, et al.25 
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Table 3. Actuarial patient survival rates after Nver transplantation for fulminant hepatic failure in 
the Pittsburah - Bavfor (Daflas) series . 
. ,c.:.': 
. ·.:.·,.·.: .... : .. :' ...... ·· .. i' Number Actuarial patient survival 
I> ··.c. .: .••• :., ..•.. : .. ." 
Drua or toxin 7 
IAcute heoatitis B (HBY) 10 
IAcute non-A non-S hepatitis 29 
Acute hepatitis A (HAY) 
Unknown 
Baylor data courtesy of Dr. Goren K1intmalm. 
to judge. In the past year, we have taken several acute 
HBV patients to the operating room for open liver biopsy 
with a donor organ available. Biopsy has accurately 
predicted recovery and transplantation was aborted. In 
other cases, severe liver damage provided confirmation 
of the need to go ahead with transplantation. 
Deepening coma, progressive renal failure, rapid 
shrinkage of the liver on serial imaging studies and un-
correctable coagulopathy are indications to press ahead 
with surgery. Rapidly progressing coma is associated 
with a poor prognosis. Although prothrombin time is an 
unreliable indicator. specific coagulation factors can be 
predictive. Factor V and factor VII levels below 20% of 
normal carry a high mortality (24.26). 
Although plasmapheresIs is of limited value In Im-
proving long term survival, it may be valuable as a tem-
porary assist for patients in fulminant failure waiting for 
transplantation. Temporary improvement in jaundice. 
lessening the severity of coma, and control of 
coagulopathy can be obtained (27). 
Sixty three patients received liver transplants for 
acute liver failure at the University of Pittsburgh or 
Baylor University Medical Center (Dallas) between 
January. 1981 and June. 1988 including 7 patients with 
drug associated failure. 10 patients with acute HBV. 29 
With acute NANB. 4 with acute HAV. and 13 with acute 
failure of unknown cause. Survival is summarized in 
Table 3. The poor results for patients with drug related 
liver failure reflect referral of patients in late stages of 
hepatic failure with grade 4 coma and patients with 
severe systemic complications. Nineteen (65.5%) of 
the 29 patients receiving transplants for acute NANB 
hepatitis, which carries a poor prognosis without 
transplantation. have survived. 
Reinfection after transplantation for acute HBV has 
been common but clinical severity has often been mild 
4 
13 
30dav One year 
57.1% 25.7% 
90.0% 80.0% 
93.1% 79.3% 
75.0% 50.0% 
53.9% 38.5% 
with many patients surviving with a low grade chronic 
hepatitis. One patient converted to an HBsAb+/HBsAg-
immune state. 
Given the poor prognosis for survival with medical 
management for many types of acute hepatic failure, 
prompt consultation with a liver transplant center is now 
an essential component in the management of ful-
minant hepatic failure. 
Liver Transplantation and Portal Hypertension 
In the past. the management of upper gastrointes-
tinal variceal hemorrhage has depended on balloon 
tamponade. selective or peripheral infusion of pitressin. 
non-selective portocaval or mesocaval shunting, selec-
tive splenorenal shunting. or esophageal transection 
and devascularization. Although each of these 
methods has been effective in control of hemorrhage. 
each has had significant drawbacks. Balloon tam-
ponade and pitressln infUSion have a high incidence of 
early rebleedlng. Non-selective shunts frequently result 
in encephalopathy and have had a high mortality. 
Selective shunting has been effective in preventing 
rebleeding. but cannot correct severe liver failure. 
Esophageal transection and devascularization proce-
dures are more Invasive and mutilating and probably 
less effective than selective shunting. and also do noth-
ing to correct severe liver failure. 
In recent years. endoscopic sclerotherapy has been 
established as an effective, relatively non-invasive 
method for the control of acute variceal hemorrhage. 
There is good eVidence that the effectiveness of 
sclerotherapy in preventing rebleeding and improving 
patient survival relates to the severity of the underlying 
liver disease (28-30). Rebleeding occurs most often, 
and after a shorter interval, and mortality is highest after 
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Fig 9. Actuarial survival for all patients un. 
dergoing sclerotherapy for variceal hemor· 
rhIIge according to Child's class. From 
Garren KO, et a/.21 
sclerotherapy in patients with the poorest hepatic 
reserve as estimated by Child's classification (Fig. 9). 
Patients requiring urgent sclerotherapy in class Band 
elective or urgent patients in class C have the worst 
results and are most likely to die of progressive hepatic 
failure within 100 days after sclerotherapy. 
Sclerotherapy alone or sclerotherapy and mesocaval 
or selective splenorenal shunts are best reserved for 
patients with good hepatic reserve unlikely to die in the 
short term of progressive liver failure. Portocaval 
shunts and esophageal transection and devasculariza-
tion procedures should be aVOided since they offer no 
advantages over these other approaches and make 
transplantation, if needed later. much more difficult. 
Sclerotherapy for acute control of bleeding followed by 
liver transplantation to prevent death from progressive 
liver failure today is the preferred treatment for high risk 
Child's class B or class C patients. 
Garrett et al (31) have recently retrospectively com-
pared the fate of 46 patients treated in Pittsburgh by 
sclerotherapy followed by liver transplantation with the 
fate of a control group of 36 non-alcoholic Child's class 
Band C patients treated with sclerotherapy alone. 
Overall survival of the transplanted group at 3 years 
was 73% compared to 17% for the non-transplanted 
group (Fig. 10). 
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Fig 10. Actuarial suMvaf for sclerotherapy 
alone versus sclerotherapy followed by liver 
fransp/anatation. From Garren KO, .t aI.11 
Iwatsuki et al (32) have recently reviewed the Pitts-
burgh experience with liver transplantation for patients 
with a previous history of bleeding esophageal varices. 
Of the first 1000 patients receiving transplants under 
cyclosporine-steroid therapy. 302 had a prior history of 
variceal bleeding, including 22 patients treated by non-
selective shunting, 15 treated with a selective shunt. 5 
treated with a non·shunting operation, and 219 treated 
by sclerotherapy. One year patient survival was 79% 
for patients with a previous history of bleeding com-
pared to 69% for those without. A prior history of bleed-
ing does not. therefore. Increase the risk of liver 
transplantation. There was. however, an increased 
early mortality in patients With a history of invaSive 
surgery for control of bleeding. Only 8% of patients 
treated without surgery died In the first month after 
transplantation compared to 17% of those who had 
surgery. 
In summary. liver transplantation is the ultimate treat-
ment of choice for patients who present with variceal 
bleeding and who are at high risk of progressive liver 
failure over the next several months. Experience sug-
gests that this includes most patients who require ur-
gent sclerotherapy in Child's class B and elective and 
urgent patients in class C. For other patients, 
sclerotherapy alone or selective shunt procedures 
which avoid the hepatic hilum are appropriate alterna-
tives. 
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Liver Transplantation for Alcoholic Cirrhosis 
Alcoholic cirrhosis is probably the most common 
cause of liver disease in our society (33) but has been 
considered a poor indication for liver transplantation be-
cause of the often advanced state of disease in al-
coholic patients, their tendency to present with a 
serious acute complication such as massive bleeding, 
massive ascites. or encephalopathy, and the high or at 
least uncertain risk of recidivism. The NIH Consensus 
Development Conference statement on liver 
Transplantation in 1983 recommended that liver 
transplantation "may be considered for the patients who 
develop evidence of progressive liver failure despite 
medical treatment and abstinence from alcohol" (34). 
Schenker (35) recommended that only patients with six 
months abstinence should be considered for liver 
tranpslantation. In fact, such a requirement would be a 
death sentence for many such patients who are too ill to 
wait so long for a transplant. 
It has been argued that transplantation of alcoholics 
might result in wastage of a limited supply of organs on 
patients whose illness is self inflicted. whose behavior is 
more likely to be noncompliant or unpredictable, and for 
whom the medical risk of transplantaion is especially 
high. However, as Atterbury (33) has cogently noted, in 
the debate over liver transplantation objective medical 
criteria for patient treatment have been tainted with 
medical care based on economic resources. chance. 
and socia! worth. 
To make matters worse, experience since 1984 sug-
gests that even medical considerations have been 
based more on presumption than fact (36.37). In 1988. 
a brief overview of the Denver-Pittsburgh experience 
with the liver transplantation for alcoholic cirrhosis was 
published (36) and demonstrated that survival and 
quality of life for 41 patients getting transplants in the 
cyclosporlne era has not been significantly different 
than for most patients getting transplants for non-al-
coholic disease. An updated survival analysis is 
presented In Fig. 11 showing survival for 73 adults get-
ting transplants for alcoholic cirrhosis between January. 
1984 and June. 1988 compared with 229 adults with 
other causes of cirrhosis (cryptogenic cirrhosis, autoim-
mune hepatitis, non-A, non-B hepatitis, but excluding 
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Fig 11. Actuarial patient survive' for adults 
after liver transplantation for Laennec's cir-
rhosis compared to non-alcoholic cirrhosis 
and al/ other non-malignant chronic liver 
diseases (Pittsburgh series). 
HBsAg positive patients) and with 318 adults with other 
benign causes of chronic liver disease (primary biliary 
cirrhosis, metabolic errors, sclerosing cholangitis, etc.) 
getting transplants in the same period. There is no sig-
nificant difference in operative or thirty day survival or in 
long term survival out to three years of follow up. Al-
though recidivism is slightly higher than previously 
reported. it still has involved only a small fraction of 
patients. With proper attention to psychiatric and social 
support. many patients with end stage alcoholic liver 
disease can be successfully managed with liver 
transplantation. 
There appears to be no valid basis for excluding al-
coholicS from liver transplantation except on the basis 
of objective conditions such as intractable, irreversible 
cardiomyopathy or central nervous system degenera-
tion that would prevent satisfactory recovery or con-
SCIOUS and deliberate refusal of the patient to cooperate 
in the process despite adequate medical and 
psychiatric input. 
as 
ISSUE IN PEDIATRIC LIVER 
TRANSPLANT ATION 
Progress continues to be made in pediatric 
transplantation and several series have now reported 
overall one year patient survivals in the 65-80% range 
(38-45). Controversy continues over the place of por-
toenterostomy in the management of biliary atresia 
given the current success of liver transplantation, and 
its current limitations because of the continued shortage 
of organs for children and factors contributing to a 
higher mortality after liver transplantation for small in-
fants. 
Biliary atresia and porfoenlerostomy 
A single attempt at portoenterostomy within 3 
months of birth is still an appropriate consideration for 
infants with extrahepatic biliary atresia, but por-
toenterostomy is stated to be successful in only 25% of 
patients on whom it is attempted (46). Thus, in the 
majority of children, adequate bile flow cannot be estab-
lished or progressive biliary cirrhosis and/or recurrent 
cholangitis with inflammatory destruction of intrahepatic 
bile ducts occurs. Repeated operations to obtain 
drainage or to vent the reconstruction make transplan-
tation much more difficult and probably should not be 
attempted in most patients. Reoperation is best limited 
lIIe 
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to patients in whom good bile flow, lost after an initially 
successful first operation, can be easily restored by 
removal of stones or correction of a technical defect. 
Reduced liver transplants 
It is estimated that 25% of the children who might 
benefit each year from a liver transplant die waiting for a 
suitable donor (47). The largest group of such children 
are infants with biliary atresia, in whom the mortality 
while waiting may be even higher. One pediatric 
program recently reported that 59% of its referrals were 
under 1 year of age, but only 18% of those who 
received transplants were in this age group because of 
the organ shortage (41). In order to meet the critical 
need for organs for these children, there has been an 
increasing trend to use reduced sized liver grafts for 
these patients, a technique first used in 1975 by Starzl. 
who transplanted an adult left lateral segment into an in-
fant with biliary atresia. Successful application of this 
technique has now been reported from centers in Brus-
sels (48,49), Chicago (SO,51), Hannover (52,53), and 
Paris (54,55), with recent mortality statistics equal to or 
better than results for whole organ transplants, and a 
reduction in waiting list mortality. 
The segmental anatomy of the liver provides con-
siderable flexibility for the surgeon in tailoring the graft 
to fit the recipient, as illustrated in Fig. 12. Other varia-
tions are possible. such as leaving the recipient's vena 
Fig 12_ Reduced liver grafts for orthotopic transplant\tion. A Right lobe graft B. Left lobe graft. 
C. Left lateral segment graft. From Broe/seh CE, et a/. 1 . 
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cava in place and piggybacking the liver onto it (56). 
This avoids some of the difficulty that may be en-
countered in interposing the vena cava from a much 
larger donor Into a small recipient. 
The use of adult livers for small children versus the 
need for grafts for adults has generated some con-
troversy (57). In addition to the question of increased 
technical risk. the use of reduced livers puts the poten-
tial recipients for these grafts in competition with other 
candidates for whole organ grafting. However. there is 
less demand for organs for larger children. and the 
safety of the technique has improved with experience. 
The use of reduced-sized grafts adds some complexity 
to the problems of recipient selection, and further em-
phasizes the need for objective criteria (58). 
Vascular thrombosis 
Fig. 13 compares the survival after liver transplanta-
tion for children. based on body weight at the time of 
transplantation in the Pittsburgh cyclosporine series. 
The figure demonstrates the high mortality for very 
small (under 7 kg) infants and intermediate mortality for 
larger infants (7 to 12 kg), compared to children over 12 
kg. Hepatic artery thrombosis and. to a lesser extent. 
portal vein thrombosis. account for much of this in-
creased mortality in smaller pediatric recipients (59.60). 
Technical failures. including errors in suture techni-
que. damage to donor or recipient vessels, and failure 
to assess arterial flow correctly. account for some 
failures. Failure to properly assess arterial or portal 
vein flow can be minimized by intraoperative use of flow 
meters (61-63). Vessels less than 3 mm in diameter. 
anastomotic revision. and use of aortic conduits or lilac 
artery grafts are also associated with a higher risk of 
thrombOSIS (64) However. other physiological factors 
also play an important role. 
Severe rejection with swelling of the liver and arterial 
constriction may result in impaired flow in the liver or 
portal vein and result in thrombosis. Furthermore. 
rejection can be associated with venous and arterial en· 
dotheliltls. resulting in thrombus formation in small- and 
medium-sized vessels of the transplanted liver. Bis-
muth (65) has reported that in 7 of 9 patients 
retransplanted for acute or chronic rejection. thrombi 
were found in the portal vein in 3. in the hepatic artery in 
3, and In both In 1. A severe endarteritis was present in 
patients with arterial thrombosis. and a phlebitis in 
patients With portal vein thrombosis. 
Cold storage, reperfusion. and cyclosporine may 
have deleterious effects on the microvasculature of the 
-
Fig 13. Pediatric survNal based on body 
wei ht. 
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liver graft and promote thombosis. Extensive injury to 
the sinusoidal lining of the liver has been shown to be a 
critical feature in a rat liver preservation model. and 
cyclosporine has been implicated in prostanoid metabo-
lism and endothelial cell injury (66-68). 
It has been known for many years that a hyper-
coagulable state may contribute to the increased risk of 
hepatic artery thrombosis after liver transplantation (69). 
Postoperative anticoagulation therapy with heparin and 
dextran may reduce the incidence of hepatic artery 
thrombosis (64). Recently. it has been reported that 
there IS a relative deficiency of protein C and antithrom-
bin. as well as impaired fibrinolysIs. in the first 10 days 
after transplantation in children (70). 
Portal vein thrombosis is less common than hepatic 
arterial thrombosis. but many of the same factors con-
tribute to both. Technical considerations include exces-
sive length or improper alignment, donor-recipient size 
discrepancy, disease of the portal vein wall. undetected 
thrombi In the mesenteric and splenic veins which later 
propagate into the portal vein. or steal of flow by large 
collaterals (71-73). 
Portal vein thrombosis may result in catastrophic 
failure with acute massive ascites or massive variceal 
bleeding. or it may be tolerated. There have been 
reports of successful thrombectomy and repair of an 
obstructed portal vein (74) and use of a splenorenal 
shunt in patients whose livers remained viable after por-
tal occlusion (75). Spontaneous recanalization of a 
thrombosed portal vein has also been reported (76). 
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The approach to be taken to portal vein thrombosis 
requires a thoughtful assessment of the patient's situa-
tion. If a correctable technical fault is present. and the 
liver has not been irreversibly damaged, direct repair 
should be considered. If the problem is physiological 
with a viable liver but persistent complications from por-
tal hypertension, a shunt procedure may be ap-
propriate. If liver function is severely compromised by 
lack of portal flow or by concomitant rejection, 
retransplantation is the treatment of choice. 
MANAGEMENT OF THE ABSENT 
PORTAL VEIN IN THE TRANSPLANT 
CANDIDATE 
Absence of a patent portal vein has until recently 
been a contraindication to liver transplantation. This is 
a common problem in children with biliary atresia in 
whom the portal vein frequently becomes atretic. It has 
been suggested that non-invasive monitoring with 
sonography of portal flow and portal flow and portal vein 
size can be a guide to the timing of transplantation in 
patients with biliary atresia (77). In patients with long 
standing end stage cirrhosis and portal hypertension. 
portal flow is severely impaired and thrombosis may 
occur. Similarly, patients who have had shunting proce-
dures with subsequent reduction of portal flow are also 
at risk. 
In long standing portal hypertension, the wall of the 
portal vein may become diseased and be unsuitable for 
suturing. even If a lumen remains. If the confluence of 
the mesenteric and splenic veins IS not involved. a 
piece of iliac vein from the liver donor can be sewn on. 
to replace the proximal recipient vein. In some cases. 
however. the confluence itself may be occluded. Starzl 
has successfully anastomosed the donor portal vein to 
a large coronary vein in a patient who is well more than 
three years after transplantation. Hiatt et al (78) have 
reported anastomosIs of the donor portal vein to a large 
choledochal vein. In many patients with this problem. 
however. it may be possible and preferable to use a 
jump graft of donor iliac vein from the superior' 
mesenteric vein to the donor portal vein (Fig. 14) (79). 
Doppler ultrasonography is a useful screening test 
for portal vein patency. but large, high flow collaterals in 
the hepatic hilum may be misinterpreted as a patent 
portal vein. Magnetic resonance imaging (MRI) is a 
more reliable non-invasive test available for assess-
ment of portal vein patency and can, in many cases, 
Fig 14. Donor iliac vein graft from SMV to 
rtal vein. 
suffice in place of angiography fer assessment of portal 
and mesenteric vein patency. 
IMMUNOSUPPRESSION AND 
IMMUNOBIOLOGY 
Immunosuppression 
The mainstay of immunosuppressive therapy in clini-
cal liver transplantation remains cyclosporine and low 
doses of prednisone. Short term high dose steroids or 
OKT3 monoclonal antibody therapy remain the 
preferred treatments for acute cellular rejection. 
However. nephrotoxicity and hypertension remain sig-
nificant problems with use of cyclosponne and there-
fore. many centers have turned to triple or quadruple 
drug regimens in an effort to manage these Side effects 
until another. less toxic agent. becomes available. 
Hypertension requiring multiple drug therapy is a fre-
quent complication after liver transplantation under 
cyclosponne. In the King's College series, the in-
cidence of hypertenSion rose from 15.3% at 3 months to 
63.6% at 4 years after transplantation in liver recipients 
maintained on cyclosporine.(80) Calcium channel 
blockers, beta blockers and diuretics, and angiotenSin 
converting enzyme (ACE) inhibitors have all been used 
to control hypertension, and therapy must be tailored to 
the individual patient. Cyclosportne dosage does not al-
ways correlate with the degree or ease of control of 
chronic hypertension after liver transplantation (81). 
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The chronic nephrotoxic effects of cyclosporine were 
eVident early in the Pittsburgh and Cambridge liver 
transplant series, and a strategy adopted was to main-
tain high cyclosporine levels early after transplantation, 
but to lower them later in order to reduce long term ef-
fects on the kidneys and to relieve hypertension (82). 
Parenteral cyclosporine is associated with more severe 
degrees of renal dysfunction (83) and therefore, another 
strategy that has been used in recent years is to avoid, 
delay, or minimize the use of intravenous cyclosporine 
In the early period after transplantation by substituting 
other therapy, especially polyclonal or monoclonal an-
tibody therapy, in the first week after transplantation 
(84-86). A third strategy is to convert from high-dose 
cyclosporine-prednisone to low-dose cyclosporine-pred-
nisone with azathioprine to minimize the chronic 
nephrotoxicity of cyclosporine (87-89). 
Meyers (90) has recently reported significant persist-
ent pathologic findings in kidneys of Stanford heart 
transplant recipients treated for 12 or more months with 
cyclosporine. Progressive, probably irreversible reduc-
tion in glomerular filtration rate (GFR), increased renal 
vascular resistance, proteinuria, and ischemic 
glomerular collapse and sclerosis were found. Eight 
percent of this group developed end stage renal failure. 
Reduction of cyclosporine dosage offered only marginal 
benefit in preventing the microvascular injury from 
chronic administration of cyclosporine. 
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Fig 15. Mean serum creatinine before and 
after Uver transplantation with cyclosporine. 
From Gonwa TA, et a/" 
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Should these findings in the Stanford heart patients 
raise concern for liver transplant patients on 
cyclosporine? Gonwa et al (91) have studied the early 
and long term effects of cyclosporine therapy on serum 
creatinine (Fig. 15) and GFR (Fig. 16). This study 
demonstrated a severe depression of GFR early after 
transplantation which persisted but did not progress at 
one and two years after transplantation. Nevertheless, 
the persistence of such a significant depression in GFR 
is noteworthy. 
The King's College group has reported reversibility 
of early cyclosporine nephrotoxicity if the drug is 
withdrawn, but a high incidence of chronic 
nephroto)(icity in patients maintained on cyclosporine 
for over 2 years (80). Experience in Pittsburgh has 
been similar (92), but end stage renal disease requiring 
renal transplantaton so far has been unusual, except in 
a small subset of patients requiring one or more 
retransplantations, usually for graft rejection. 
Children after liver transplantation have a much 
higher and more variable mean cyclosporine clearance 
per kilogram of body weight than adults (93). In addi-
tion, the Roux-en-Y choledochojejunostomy for biliary 
reconstruction frequently used in pediatric patients, is 
associated with decreased bioavailability of 
cyclosporine (94,95). Thus, pediatric liver transplant 
reCipients usually require higher doses of intravenous 
and oral cyclosporine doses, and a longer period of ini-
tial therapy with intravenous cyclosponne. 
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Fig 16. Mean glomerular filtration rate 
(GFR) before and afre' liver transplantation 
with cyclosporine. From Gonwa TA, et al.·' 
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The most promising new drug on the horizon is 
FK506. a macrolide antibiotic produced by Strep-
tomyces tsukubaensis (96.97). It has been 
demonstrated to have a synergistic activity with 
cyclosporine in animal allograft models (98). In vitro. 
cyclosporine resistant alloreactive lymphocyte clones 
appear to be sensitive to FK506 (99). In the most 
recent studies. the drug has produced excellent survival 
of kidney allografts in outbred baboons with minimal 
toxicity (100). Phase 1 clinical trials in kidney and liver 
transplantation recently began in Pitlsburgh. 
Is there hyperacute rejection of the liver? 
It is now well established that there is an increased 
risk associated with liver transplantation between ABO 
mismatched and/or incompatible donors (101-103). A 
graft versus host, anti-ABO blood group antibody 
mediated hemolytic reaction may be seen after liver 
transplantation across an ABO compatible mismatch 
(104), and in some cases, can be severe enough to be 
life threatening (105,106). Aggressive therapy with 
mannitol and diuretics, plasmapheresis, transfusion with 
donor ABO blood group red cells and, in some cases, 
retransplantation can be required. Some of the in-
creased risk demonstrated lor transplantation across an 
ABO compatible mismatch may be a consequence of 
this graft versus host reaction. 
Transpiantation between an ABO incompatible donor 
and recipient may have more serious consequences. 
Recent studies of liver tranplantations across an ABO 
incompatibility found a marked increased incidence of 
acute graft failure compared to a matched control group 
of age. sex. clinical priority. and antibody cross-match 
negative ABO compatible transplants (107,108). Failed 
grafts demonstrated widespread hemorrhagic necrosis 
with diffuse intrahepatic coagulation. Tissue bound. 
donor specific isoagglutinins were found on elution 
studies and marked antibody and complement deposi-
tion were seen in arteries on immunofluorescent stain. 
ing These findings are highly suggestive of an an-
tibody mediated early graft destruction which cannot 
necessarily be predicted preoperatively, but which is a 
significant risk when transplantation is carried out 
across an ABO incompatibility. Bismuth has recently 
also reported accelerated rejection with hemorrhagic 
necrOSIS in 4 of 11 ABO incompatible liver transplanta-
tions for fulminant hepatic failure (109). 
Liver transplantation across a positive Iymphocytoxic 
antibody crossmatch has not been associated with 
decreased graft survival or predictable hyperacute' graft 
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loss (110). although patients with a high panel reactive 
antibody titer tend to have higher intraoperative blood 
loss and more problems with platelet transfusions than 
patients with low titers (111). Furthermore. a liver 
transplant graft performed before a kidney transplant 
from the same donor in a recipient with a positive donor 
specific crossmatch will usually protect the kidney from 
hyperacute rejection (112). 
It is postulated that the liver either absorbs and 
neutralizes circulating anti-donor antibody and/or 
releases soluble donor antigens which have a protec-
tive effect. High levels of Circulating donor HLA an-
tigens which persist for years can be demonstrated in 
reCipient sera within 24 hours of the transplantation of 
the liver (113). However. there have been exceptional 
cases in which both organs have failed with hemor-
rhagic necrosis of the liver and typical hyperacute rejec-
tion of the kidney (114). 
In both a rat model (115) and a primate model (116). 
it has been possible to pre sensitize liver recipients with 
prior skin grafts from a liver donor and produce findings 
similar to those seen in the human cases in which hy-
peracute rejection has been suspected. It thus appears 
that hyperacute rejection of the liver is a real 
phenomenon. but the conditions under which it occurs 
in the clinical setling and the factors that determine out-
come remain poorly defined. Only ABO incompatibility 
has been established as a significant risk factor. 
Can primary graft failure be predicted? 
A reliable test of liver viability that can be applied 
preoperatively has yet to be developed. Efforts to 
predict the quality of early graft function from conven-
tional clinical parameters such as liver function tests. 
systemic cardiopulmonary parameters and acid·base 
balance. cause of donor death. length of cardiac arrest. 
or pressor requirement have been unsuccessful (117-
119). Assessment of bile production after revas-
cularization rema;ns the Simplest and most reliable clini-
cal parameter of liver graft viability after transplantation. 
and in a rat model bile flow has been shown to correlate 
with liver cellular ATP levels and graft survival (120). 
Moreover. cellular ATP levels in biopsies of donor livers 
have been reported to predict graft performance in a 
recent clinical study (121). Depression of factor V 
below 20% of normal and factor VII below 10% of nor-
mal are accurate predictors of graft failure after 
transplantation. especially when aspartate 
aminotransferase CAST) is also high (over 5000 I.U.), 
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but these indicators still have approximately 30% false 
positive rates (122). 
One of the more promising approaches to develop-
ment of a reliable assay of graft viability has been to 
study the clearance of lidocaine by the liver. A TDX 
fluorescent polarization assay of monoethyl-
glycinexylidide (MEGX) concentration in serum 15 
minutes after injection of a lidocaine bolus has been 
shown to be a sensitive indicator of hepatic function and 
predicted primary function in 32 of 37 cases and 
primary failure In 4 of 6 cases (123). MEGX formation 
appears to correlate with the oxidative metabolizing 
capacity of the liver graft (124). In another study, seven 
donors whose livers were discarded on the basis of 
conventional clinical criteria were found to have MEGX 
serum concentrations comparable to accepted donors, 
suggesting that this assay may be valuable in prevent-
ing inappropriate discards of viable organs (125). 
Liver preservation--the UW solution 
The recent introduction by Belzer and his associates 
(126-128) of a new cold-storage solution, the "UW solu-
tion," represents the first major innovation in liver 
preservation since the first descriptions of slush preser-
vation more than 1 0 years ago (129-130). Lac-
tobionate. raffinose, and glutathione are believed to be 
the essential components of the UW solution (131-132). 
Lactobionate.a large and relatively impermeable anion. 
and raffinose, a large molecular mass saccharide. 
provide osmotic support and prevent cellular swelling. 
Glutathione is needed for reduction of cytotoxic 
molecules. such as hydrogen peroxide, lipid peroxides. 
disulfides. ascorbate. and free radicals. UW solution 
does not contain glucose. which is more easily metabo-
lized to lactiC acid by the cold preserved liver than by 
the kidney (131). 
The Pittsburgh liver group recently reported com-
parison of 185 cadaveric liver allografts procured using 
UW solution compared to 180 cadaveric grafts procured 
in the immediately prior period using Euro-Collins solu-
tion (133). Preservation times ranged from 3 to 9 1/2 
hours in the Euro-Collins group. but 44% of the UW 
preserved livers were stored for more than 9 112 hours, 
with a maximum extending out to 24 hours. Despite the 
much longer preservation times. patient survival was 
equivalent and graft survival superior, with lower rates 
of primary non-function and retransplantation in the UW 
preserved group. 
The extended and higher quality of liver preservation 
now possible with the UW solution will have great im-
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pact on the practice of liver transplantation. In addition 
to the convenience and economy afforded by being 
able to work in a more manageable time frame. the su-
perior preservation provided by this remarkable solution 
should permit further liberalization of the criteria for 
donor acceptability. 
AUXILIARY LIVER 
TRANSPLANTATION 
Almost all of the progress in liver transplantation in 
this past decade has been orthotopic replacement of 
the native liver. but recently there has been a renewed 
interest in auxiliary liver transplantation (134). This 
technique is attractive in that failure of the graft might 
not lead to sudden death of the patient or require im-
mediate retransplantation, the operative risk might be 
reduced by avoidance of a difficult total hepatectomy. 
and matching of donor and recipient for size might be 
less of a problem if partial liver grafts are used. 
Terpstra et al (135) have recently reported a suc-
cessful series of six patients treated with auxiliary par-
tial liver transplantation, who were considered too high 
a risk for an orthotopic procedure. In their operation 
(Fig. 17), after the removal of the gallbladder and seg-
ments II and III of the graft. a short cuff of suprahepatic 
graft vena cava is anastomosed to the side of the host 
Fig 17. Auxiliary liver transplantation. 
From Terpstra OT, et a/. '35 
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portal vein. The hepatic artery is placed end to side on 
the infrarenal aorta. Biliary reconstruction is by Roux-
en-Y choledochojejunostomy. All patients were surviv-
ing at 5 to 14 months after surgery. Mean operating 
time was 7,9 hours (range, 7 to 9) and mean blood loss 
was 12.7 units (range, 10 to 22). 
The patients reported in this series would today not 
be considered prohibitive risks for orthotopic transplan-
tation in Pittsburgh, and the reported range of operative 
time and blood loss is comparable to results being 
achieved today in Pit1sburgh and elsewhere. Neverthe-
less, the results are encouraging, and further work will 
bet1er define the proper indications for this procedure. 
SUMMARY 
After liver transplantation for cancer, there is a 
high incidence of disease recurrence within 18 to 36 
months for most tumors, although there are a small 
number of long-term survivors. An extended resec-
tion of the upper abdominal viscera with replacement 
by a liver-pancreas cluster is being tried in Pittsburgh 
for lesions which have not been successfully 
managed with liver transplantation alone. 
Despite a high incidence of graft reinfection after 
liver transplantation for hepatitis B virus (HBV) re-
lated disease, a significant proportion of patients 
achieve long-term survival. Hyperimmune globulin 
and interferon have been of little benefit in preventing 
reinfection. Clinical trials with a human monoclonal 
antibody to HBsAg are in progress. 
Transplantation for alcoholic liver disease has 
been considered controversial. However, survival 
after liver transplantation for Laennec's cirrhosis IS 
comparable to survival after liver transplantation for 
other chroniC, benign. and non-HBV related liver dis-
eases, 
Sclerotherapy followed by liver transplantation IS 
the treatment of chOice for patients with acute hemor-
rhage from esophageal varices and end-stage liver 
disease. Sclerotherapy alone or followed by selec-
tive shunting is an appropriate alternative in patients 
with good hepatic reserve. 
Only 25% of infants with biliary atresia benefit 
from portoenterostomy. To meet the demand for 
small infants waiting for transplantation, several 
transplant programs have successfully expanded 
their efforts to use partial (reduced) liver grafts. 
Cyclosporine and low-dose prednisone remain 
the basis for immunosuppression after liver 
transplantation. However, nephrotoxicity and hyper-
tension are frequent and troublesome side effects of 
cyclosporine. Triple and quadruple drug regimens 
have been increasingly popular in an effort to mini-
mize cyclosporine toxicity. Phase 1 clinical trials with 
a new drug, FKS06, recently began in Pittsburgh. 
Hyperacute rejection of the liver has been 
demonstrated In animal models and has been 
strongly suspected in recent clinical descriptions of 
acute hemorrhagic necrosis after liver transplanta-
tion. So far. only transplantation across an ABO in-
compatibility has been identified as a risk factor for 
hyperacute rejection. 
The new p'eservatlon solution developed by Bel· 
zer and associates at the UniverSity of WisconSin 
has significantly extended the preservation time for 
liver grafts, and Improved the quality of liver preser-
vation. 
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